Dataset for the reporting of carcinoma of the esophagus in resection specimens: recommendations from the International Collaboration on Cancer Reporting.


Journal

Human pathology
ISSN: 1532-8392
Titre abrégé: Hum Pathol
Pays: United States
ID NLM: 9421547

Informations de publication

Date de publication:
08 2021
Historique:
received: 27 04 2021
accepted: 06 05 2021
pubmed: 17 5 2021
medline: 29 12 2021
entrez: 16 5 2021
Statut: ppublish

Résumé

A standardized data set for esophageal carcinoma pathology reporting was developed based on the approach of the International Collaboration on Cancer Reporting (ICCR) for the purpose of improving cancer patient outcomes and international benchmarking in cancer management. The ICCR convened a multidisciplinary international expert panel to identify the best evidence-based clinical and pathological parameters for inclusion in the data set for esophageal carcinoma. The data set incorporated the current edition of the World Health Organization Classification of Tumours of the Digestive System, and Tumour-Node-Metastasis staging systems. The scope of the data set encompassed resection specimens of the esophagus and esophagogastric junction with tumor epicenter ≤20 mm into the proximal stomach. Core reporting elements included information on neoadjuvant therapy, operative procedure used, tumor focality, tumor site, tumor dimensions, distance of tumor to resection margins, histological tumor type, presence and type of dysplasia, tumor grade, extent of invasion in the esophagus, lymphovascular invasion, response to neoadjuvant therapy, status of resection margin, ancillary studies, lymph node status, distant metastases, and pathological staging. Additional non-core elements considered useful to report included clinical information, specimen dimensions, macroscopic appearance of tumor, and coexistent pathology. This is the first international peer-reviewed structured reporting data set for surgically resected specimens of the esophagus. The ICCR carcinoma of the esophagus data set is recommended for routine use globally and is a valuable tool to support standardized reporting, to benefit patient care by providing diagnostic and prognostic best-practice parameters.

Sections du résumé

BACKGROUND AND OBJECTIVES
A standardized data set for esophageal carcinoma pathology reporting was developed based on the approach of the International Collaboration on Cancer Reporting (ICCR) for the purpose of improving cancer patient outcomes and international benchmarking in cancer management.
MATERIALS AND METHODS
The ICCR convened a multidisciplinary international expert panel to identify the best evidence-based clinical and pathological parameters for inclusion in the data set for esophageal carcinoma. The data set incorporated the current edition of the World Health Organization Classification of Tumours of the Digestive System, and Tumour-Node-Metastasis staging systems.
RESULTS
The scope of the data set encompassed resection specimens of the esophagus and esophagogastric junction with tumor epicenter ≤20 mm into the proximal stomach. Core reporting elements included information on neoadjuvant therapy, operative procedure used, tumor focality, tumor site, tumor dimensions, distance of tumor to resection margins, histological tumor type, presence and type of dysplasia, tumor grade, extent of invasion in the esophagus, lymphovascular invasion, response to neoadjuvant therapy, status of resection margin, ancillary studies, lymph node status, distant metastases, and pathological staging. Additional non-core elements considered useful to report included clinical information, specimen dimensions, macroscopic appearance of tumor, and coexistent pathology.
CONCLUSIONS
This is the first international peer-reviewed structured reporting data set for surgically resected specimens of the esophagus. The ICCR carcinoma of the esophagus data set is recommended for routine use globally and is a valuable tool to support standardized reporting, to benefit patient care by providing diagnostic and prognostic best-practice parameters.

Identifiants

pubmed: 33992659
pii: S0046-8177(21)00076-9
doi: 10.1016/j.humpath.2021.05.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

54-65

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Alfred K Lam (AK)

Pathology, School of Medicine and Dentistry, Gold Coast Campus, Griffith University, Gold Coast, Queensland, 4222, Australia; Pathology Queensland, Gold Coast University Hospital, Southport, Queensland, 4222, Australia; Faculty of Medicine, The University of Queensland, Herston, Queensland, 4006, Australia. Electronic address: a.lam@griffith.edu.au.

Michael J Bourke (MJ)

Westmead Hospital, Department of Gastroenterology and Hepatology, Sydney, New South Wales, 2145, Australia; University of Sydney, Westmead Clinical School, Sydney, New South Wales, 2145, Australia. Electronic address: michael@citywestgastro.com.au.

Renyin Chen (R)

Department of Pathology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, Henan Province, PR China. Electronic address: chenrenyin@zzu.edu.cn.

Roberto Fiocca (R)

Department of Pathology, University of Genova and IRCCS Policlinico San Martino, 16132, Genova, Italy. Electronic address: fiocca@unige.it.

Fumiyoshi Fujishima (F)

Department of Pathology, Tohoku University Hospital, Aoba-ku, Sendai, 980-8574, Japan. Electronic address: ffujishima@patholo2.med.tohoku.ac.jp.

Satoshi Fujii (S)

Department of Molecular Pathology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan; Department of Pathology and Clinical Laboratories, National Cancer Centre Hospital East, Kashiwa, 6-5-1, Japan. Electronic address: sfujii@yokohama-cu.ac.jp.

Marnix Jansen (M)

University College London (UCL) Cancer Institute, London, United Kingdom; University College London Hospitals NHS Trust, London, WC1E 6DD, United Kingdom. Electronic address: m.jansen@ucl.ac.uk.

Priyanthi Kumarasinghe (P)

PathWest Laboratory Medicine, PathWest QEII Medical Centre, Perth, 6009, Western Australia, Australia. Electronic address: priyanthi.kumarasinghe@health.wa.gov.au.

Rupert Langer (R)

Institute of Pathology, University of Bern, 3012 Bern, Switzerland. Electronic address: rupert.langer@kepleruniklinikum.at.

Simon Law (S)

Queen Mary Hospital, The University of Hong Kong, Hong Kong, China. Electronic address: slaw@hku.hk.

Sybren L Meijer (SL)

Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, 1105, AZ, the Netherlands. Electronic address: s.l.meijer@amsterdamumc.nl.

Cian Muldoon (C)

Histopathology Department, St James's Hospital, Dublin, D08 NHY1, Ireland. Electronic address: cmuldoon@stjames.ie.

Marco Novelli (M)

Research Department of Pathology, University College London Medical School, London, WC1E 6DD, United Kingdom. Electronic address: m.novelli@ucl.ac.uk.

Chanjuan Shi (C)

Department of Pathology, Duke University School of Medicine, Durham, NC, 27708, United States. Electronic address: Chanjuan.shi@duke.edu.

Laura Tang (L)

Department of Pharmacy, Memorial Sloan Kettering Cancer Centre, New York City, NY, 10065, United States. Electronic address: tangl@mskcc.org.

Iris D Nagtegaal (ID)

Department of Pathology, Radboud University Medical Centre, Nijmegen, 6500, the Netherlands. Electronic address: Iris.Nagtegaal@radboudumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH